Journal: STAR Protocols

Article Title: Protocol to create isogenic disease models from adult stem cell-derived organoids using next-generation CRISPR tools

doi: 10.1016/j.xpro.2024.103189

Figure Lengend Snippet:

Article Snippet: TGF-α , PeproTech , 100-16A.

Techniques: Virus, Subcloning, Recombinant, Membrane, Ligation, Plasmid Preparation, Software, Suspension, Electroporation, Sterility, Flow Cytometry, Fluorescence, Microscopy, Imaging

Journal: Molecules

Article Title: An Insight into the Anticancer Activities of Ru(II)-Based Metallocompounds Using Docking Methods

doi: 10.3390/molecules180910829

Figure Lengend Snippet: The binding energy of the metallocompounds from the Autodock docking of hydrated complexes.

Article Snippet: Also, the binding affinities of both hydrated and non-hydrated metallocompounds 16 and 16a respectively are higher than that of metallocompounds 15 and 15a by the Molegro, which further agrees with the experimental reports [ ].

Techniques: Binding Assay

Journal: Molecules

Article Title: An Insight into the Anticancer Activities of Ru(II)-Based Metallocompounds Using Docking Methods

doi: 10.3390/molecules180910829

Figure Lengend Snippet: The binding energy of the metallocompounds from the relaxed Molgro docking for hydrated compounds.

Article Snippet: Also, the binding affinities of both hydrated and non-hydrated metallocompounds 16 and 16a respectively are higher than that of metallocompounds 15 and 15a by the Molegro, which further agrees with the experimental reports [ ].

Techniques: Binding Assay

Journal: Molecules

Article Title: An Insight into the Anticancer Activities of Ru(II)-Based Metallocompounds Using Docking Methods

doi: 10.3390/molecules180910829

Figure Lengend Snippet: The binding affinities of the metallocompounds from the covalent constrained Molegro docking of hydrated complexes.

Article Snippet: Also, the binding affinities of both hydrated and non-hydrated metallocompounds 16 and 16a respectively are higher than that of metallocompounds 15 and 15a by the Molegro, which further agrees with the experimental reports [ ].

Techniques: Binding Assay

Journal:

Article Title: Pharmacological characterization of a selective agonist for Bombesin Receptor Subtype - 3

doi: 10.1016/j.bbrc.2009.07.006

Figure Lengend Snippet: (A) Structure of compound 16a [8]. R1 = CH3, R2 = Benzyl. (B) Comparison of the calcium mobilization effects of compound 16a, dY-Bn(6–14), and bombesin on HEK293T cells transiently transfected with hBRS-3. Compound 16a has comparable potency as dY-Bn(6–14). Bombesin activates hBRS-3 with low potency. All data represent at least three experiments in triplicates. Data are shown as mean ± S.E.M. Dose-response curves were generated using Prism. See Table 1 for comparisons of EC50 values.

Article Snippet: Compound 16a was purchased from Bachem (Torrance, CA). dY-Bn(6–14), bombesin, NMB, orexin, dopamine, kisspeptin, melatonin were purchased from Phoenix (Burlingame, CA).

Techniques: Comparison, Transfection, Generated

Journal:

Article Title: Pharmacological characterization of a selective agonist for Bombesin Receptor Subtype - 3

doi: 10.1016/j.bbrc.2009.07.006

Figure Lengend Snippet: Comparison of Agonist Activity in Functional FLIPR Assays

Article Snippet: Compound 16a was purchased from Bachem (Torrance, CA). dY-Bn(6–14), bombesin, NMB, orexin, dopamine, kisspeptin, melatonin were purchased from Phoenix (Burlingame, CA).

Techniques: Comparison, Activity Assay, Functional Assay

Journal:

Article Title: Pharmacological characterization of a selective agonist for Bombesin Receptor Subtype - 3

doi: 10.1016/j.bbrc.2009.07.006

Figure Lengend Snippet: Comparison of the calcium mobilization effects of compound 16a on BRS-3, NMB-R and GRP-R. (A) and (B), compound 16a, dY-Bn(6–14), and bombesin at rat (A) and mouse (B) BRS-3 transiently transfected in HEK293T cells. Compound 16a shows greater potency than bombesin or dY-Bn(6–14). (C) HEK293T cells were transiently transfected with rNMB-R. At concentrations as high as 10 µM, compound 16a failed to elicit intracellular calcium release, while NMB caused a dose-dependent increase in intracellular calcium. (D) HEK293T cells were transiently transfected with hGRP-R. Compound 16a had no effect on intracellular calcium release, even at 10 µM, while bombesin, a potent agonist at GRP-R, produced a dose-dependent receptor activation. All data represent at least three experiments in triplicates. Data are shown as mean ± S.E.M. Dose-response curves were generated using Prism. See Table 1 for comparison of EC50 values.

Article Snippet: Compound 16a was purchased from Bachem (Torrance, CA). dY-Bn(6–14), bombesin, NMB, orexin, dopamine, kisspeptin, melatonin were purchased from Phoenix (Burlingame, CA).

Techniques: Comparison, Transfection, Produced, Activation Assay, Generated

Journal:

Article Title: Pharmacological characterization of a selective agonist for Bombesin Receptor Subtype - 3

doi: 10.1016/j.bbrc.2009.07.006

Figure Lengend Snippet: Selectivity profile of compound 16a

Article Snippet: Compound 16a was purchased from Bachem (Torrance, CA). dY-Bn(6–14), bombesin, NMB, orexin, dopamine, kisspeptin, melatonin were purchased from Phoenix (Burlingame, CA).

Techniques: Activity Assay

Journal:

Article Title: Pharmacological characterization of a selective agonist for Bombesin Receptor Subtype - 3

doi: 10.1016/j.bbrc.2009.07.006

Figure Lengend Snippet: Agonist-induced β-arrestin2-GFP translocation and BRS-3 internalization in HEK293 cells. (A) HEK293 cells were transiently transfected with HA-tagged rBRS-3 and GFP tagged β-arrestin2 (βarr2-GFP). Confocal microscopy was used to obtain real-time imaging of the cells before (first two panels at time 0 (T=0)) and after 1 µM agonist treatment at room temperature (times indicated in minutes). The first panel represents cell surface staining of Alexafluor 568-conjugated anti-HA antibody to demonstrate that the receptor is co-expressed with the βarr2-GFP. The top row demonstrates how some cells show puncta formation prior to drug treatment, while other cells (inset enlarged 2X below) reveal translocation after compound 16a (1 µM) treatment within 5 min (second row, white arrow, punctuate accumulation at membrane). (B) Overexpression of GRK2 improves the detection of βarr2-GFP translocation in HEK293 cells expressing untagged BRS-3 and βarr2-GFP. (C) Treatment with compound 16a (1 µM, up to 2 h) does not lead to internalization of the N-terminally HA-tagged rBRS-3 as visualized by Alexafluor 488-conjugated anti-HA antibody labeling of live cells.

Article Snippet: Compound 16a was purchased from Bachem (Torrance, CA). dY-Bn(6–14), bombesin, NMB, orexin, dopamine, kisspeptin, melatonin were purchased from Phoenix (Burlingame, CA).

Techniques: Translocation Assay, Transfection, Confocal Microscopy, Imaging, Staining, Membrane, Over Expression, Expressing, Antibody Labeling

Journal:

Article Title: Pharmacological characterization of a selective agonist for Bombesin Receptor Subtype - 3

doi: 10.1016/j.bbrc.2009.07.006

Figure Lengend Snippet: Effects of compound 16a administration on locomotor activity in mice. (A) Locomotion of mice after i.p. administration of vehicle (10% Tween 20) or 10 mg/kg of compound 16a. Distance traveled and stereotypic counts were monitored for 90 min after i.p. administration (each data point represents mean ± S.E.M., each treatment group n=7). (B) Effects of i.c.v. administration of compound 16a on distance traveled and stereotypic counts. Mice were monitored for 90 min after the administration of 2 µl of vehicle (10% DMSO, 1% Tween 80, n = 4) or 5 nmol of compound 16a (n = 5).

Article Snippet: Compound 16a was purchased from Bachem (Torrance, CA). dY-Bn(6–14), bombesin, NMB, orexin, dopamine, kisspeptin, melatonin were purchased from Phoenix (Burlingame, CA).

Techniques: Activity Assay

Journal: JAAOS Global Research & Reviews

Article Title: Association of Patient-reported Outcomes With Clinical Outcomes After Distal Humerus Fracture Treatment

doi: 10.5435/JAAOSGlobal-D-19-00122

Figure Lengend Snippet: Clinical Outcomes of Responders Versus Nonresponders and Patient-reported Functional Outcome of Responders

Article Snippet: PROMIS UE 16a , 40.8 ± 12.4 , — , .

Techniques: Functional Assay

Journal: JAAOS Global Research & Reviews

Article Title: Association of Patient-reported Outcomes With Clinical Outcomes After Distal Humerus Fracture Treatment

doi: 10.5435/JAAOSGlobal-D-19-00122

Figure Lengend Snippet: Multivariable Analysis of the Association Between Clinical Outcomes and Patient-reported Functional Outcomes Adjusted for Sociodemographic and Clinical Factors

Article Snippet: PROMIS UE 16a , 40.8 ± 12.4 , — , .

Techniques: Functional Assay